About Mallinckrodt pharmaceuticals
Mallinckrodt Pharmaceuticals: Simplifying Healthcare for Over 150 Years
Mallinckrodt Pharmaceuticals is a global specialty pharmaceutical company that has been making the complex simple for more than 150 years. The company is committed to improving the lives of patients by developing innovative therapies and providing high-quality healthcare products.
With a focus on pain management, autoimmune and rare diseases, Mallinckrodt has become a trusted name in the healthcare industry. The company's mission is to provide effective treatments that improve patient outcomes and enhance quality of life.
History
Mallinckrodt was founded in St. Louis, Missouri in 1867 by Edward Mallinckrodt Sr., who was a chemist and businessman. The company started as a small chemical manufacturing business but quickly grew into one of the largest pharmaceutical companies in the world.
Over the years, Mallinckrodt has expanded its operations globally through strategic acquisitions and partnerships. Today, it operates in more than 40 countries around the world with over 3,500 employees dedicated to improving patient care.
Products
Mallinckrodt offers a wide range of products across various therapeutic areas including pain management, autoimmune diseases, respiratory disorders, central nervous system disorders and hospital products.
The company's flagship product is Acthar Gel (repository corticotropin injection), which is used to treat multiple sclerosis relapses, infantile spasms and other conditions. Acthar Gel has been approved by the U.S Food & Drug Administration (FDA) since 1952.
In addition to Acthar Gel, Mallinckrodt also offers other innovative therapies such as INOMAX (nitric oxide) gas for inhalation used to treat newborns with hypoxic respiratory failure associated with pulmonary hypertension; OFIRMEV (acetaminophen) injection used for acute pain relief; THERAKOS Photopheresis System used for treatment of cutaneous T-cell lymphoma; among others.
Research & Development
Mallinckrodt invests heavily in research & development activities aimed at discovering new treatments that can improve patient outcomes. The company's R&D efforts are focused on developing therapies for rare diseases where there are few or no treatment options available today.
In addition to internal R&D activities, Mallinckrodt also collaborates with academic institutions and other industry partners through licensing agreements or joint ventures aimed at advancing scientific knowledge towards better health outcomes.
Corporate Social Responsibility
As part of its commitment towards social responsibility initiatives,Mallinkcrotdt supports various charitable organizations aroundthe world.Thecompanyhasastrongfocusonimprovinghealthcareaccessandqualityoflifeofpatientsglobally.In2019,thecompanydonatedover$1milliontocharitableorganizationsincludingtheAmericanRedCrossandDirectReliefamongothers.Malinncrkodtalsopartnerswithvariousnon-profitorganizationstosupportpatientadvocacygroupsanddiseaseawarenesscampaignsacrossvariousgeographieswhereitoperates.
Conclusion
In conclusion,MallinkcrotdtPharmaceuticalsisoneofthetopglobalpharmaceuticalcompaniesdedicatedtoimprovingpatientoutcomesbydevelopinginnovativetherapiesforrarediseases,painmanagement,andautoimmunediseases.Thecompanyhasbeenattheforefrontofhealthcareinnovationforover150years,andcontinuestobuildonitslegacybyinvestingheavilyintoresearch&developmentactivitiesaimedatdiscoveringnewtherapiesthatcanimprovepatientoutcomes.Malinncrkodtalsonotonlyfocusesonprovidinghigh-qualityhealthcareproductsbutalsocontributestosocialresponsibilityinitiativesgloballythroughsupportingcharitableorganizationsandpartnershipsaimedatimprovingaccessandqualityoflifeforallpatientsacrossvariousgeographieswhereitoperates.TolearnmoreaboutMalincrkodtPharmaceuticalsanditsproductportfoliovisittheirwebsiteorcontactthemdirectly."
mallinckrodt.com
